Health Canada's 2025 CBD Proposal: Where It Stands Now

In March 2025, Health Canada opened a consultation that many in the wellness and cannabis industries had waited years to see. The question was simple to state and hard to answer: should some cannabidiol (CBD) products be sold without a prescription, the way vitamins and other natural health products already are? For a market that has grown quickly but stayed locked inside the cannabis framework, the proposal looked like a turning point.

More than a year later, the picture is very different from the optimistic headlines. The consultation happened, the feedback came in, and then the initiative quietly lost momentum. If you run a CBD business, or plan to launch one, you need an accurate read on what was proposed, what has actually changed, and what has not. This guide gives you that, based on Health Canada's own published documents.

Executive Summary

In 2025 Health Canada explored a regulatory pathway to allow certain CBD health products to be sold without a prescription, for both human and animal use, to treat minor ailments backed by evidence. For people, the plan was to amend the Natural Health Products framework to include CBD as a medicinal ingredient. For animals, CBD products would be regulated as non-prescription veterinary drugs. After the consultation closed in June 2025, Health Canada reported that developing the pathway would require significant scientific, policy and regulatory resources that are not available at this time. The initiative was then dropped from Health Canada's Forward Regulatory Plan. As of mid-2026, CBD remains a controlled substance under the Cannabis Act, and no CBD product is authorized as a natural health product.

What Was the 2025 CBD Proposal?

What it is: a discussion paper and consultation exploring a non-prescription pathway for CBD health products. Why it matters: it would have opened retail and wellness channels that are currently closed to CBD. What to do: understand the proposal, but plan around the rules that are actually in force.

On 7 March 2025, Health Canada published a discussion paper, Towards a pathway for health products containing cannabidiol, and invited feedback until 5 June 2025. The goal was to enable access to safe, effective and high-quality CBD products for human and animal use to treat specific or minor ailments supported by adequate evidence, while protecting public health.

For human use, Health Canada proposed amending the existing Natural Health Products framework to include CBD as a medicinal ingredient, with extra premarket measures to support quality and to bridge the Food and Drugs Act and the Cannabis Act. For animal use, it explored regulating CBD products as non-prescription veterinary drugs under the Food and Drug Regulations. The paper also floated burden-reduction ideas, such as not carrying over cannabis drug and research licensing requirements for parties that only handle CBD.

The Science Behind the Proposal

What it is: the scientific advice that shaped the proposed dose and safety limits. Why it matters: it explains both the promise of CBD and the evidence gaps that slowed the pathway. What to do: use the science to set realistic product and evidence plans.

The proposal did not appear from nowhere. After the Cannabis Act came into force, Health Canada added all phytocannabinoids, including CBD, to the Prescription Drug List in 2018 because the evidence was not strong enough to support non-prescription status. It then created a Science Advisory Committee on Health Products Containing Cannabis (SAC-HPCC), which published its CBD review in July 2022.

For human use, the committee concluded that low doses of CBD, a maximum of 200 mg a day taken orally for up to 30 days, are safe and tolerable for healthy adults, while cautioning that this did not apply to vulnerable groups such as pregnant people or those with underlying conditions. For animal use, a subcommittee found that very low oral doses, between 0.2 and 2 mg per kg twice daily, were supported by safety evidence, and that there was enough evidence for CBD's efficacy in treating pain from diagnosed osteoarthritis, with veterinary oversight still important. Both groups flagged major evidence gaps, especially around drug interactions and long-term safety.

Current Rules vs the 2025 Proposal

What Happened: The Pathway Has Stalled

What it is: the current status of the proposal. Why it matters: the change many expected is not coming soon. What to do: plan around the status quo, not the proposal.

The consultation closed on 5 June 2025, and Health Canada reviewed the feedback. In its summary of what it heard, the department concluded that developing the policy and regulatory pathway would require significant, dedicated scientific, policy and regulatory resources that are not available at this time. In plain terms, the work is real, but it is not resourced.

The signal became clearer at the end of 2025. Health Canada's Forward Regulatory Plan, which for several years had referenced a proposed approach for CBD health products without practitioner oversight, no longer includes that objective. The department has said it still recognizes the importance of the work, but it is prioritizing other commitments, including Red Tape Review efforts to reduce burden for natural health products and non-prescription drugs. For now, the CBD pathway is on the shelf.

How CBD Is Regulated in Canada Today

What it is: the framework that still governs CBD. Why it matters: nothing about the proposal changed the law. What to do: operate within the cannabis framework and avoid unauthorized claims.

CBD remains a controlled substance under the Cannabis Act and the Cannabis Regulations. It can only be produced by federally licensed processors and sold through provincially authorized cannabis retailers or the medical stream. No CBD product is approved as a natural health product, and CBD cannot legally be added to foods, to cosmetics carrying health claims, or to natural health products sold outside the cannabis system.

That matters because the gap the proposal aimed to fill is still open. Many consumers want over-the-counter CBD, and many businesses want to supply it, but the legal routes remain the cannabis framework. Making a health claim for a CBD product outside an authorized drug or cannabis pathway is a compliance risk, and Health Canada continues to act against unauthorized products. Our overview of how effective the NHP regulations are explains the framework the proposal would have used.

A Brief Timeline of Canada's CBD Pathway

The 2025 consultation was one step in a long process that stretches back to legalization. Seeing the full arc helps explain both why expectations ran high and why the pause is less surprising than it first appears.

The pattern is telling. Health Canada has repeatedly acknowledged demand and even received supportive scientific advice, yet each step forward has been checked by the same obstacle: not enough high-quality evidence on safety, efficacy and drug interactions to justify removing practitioner oversight. The 2025 consultation did not resolve that gap, and the department has been candid that closing it would take dedicated resources it cannot commit right now. For businesses, the lesson is to treat evidence generation, not lobbying, as the real key to any future pathway, and to keep watching the regulatory plan for the moment priorities shift.

What This Means for Your Business

For CBD companies, the stalled pathway is frustrating, but it is also clarity. Planning a product line around a non-prescription NHP route that does not exist is a real risk. The safer strategy is to build within the current cannabis framework while keeping your quality systems ready to pivot if the pathway revives. If export is part of your plan, our comparison of EU-GMP and GPP shows how to build for higher standards from the start.

• The status quo holds. CBD stays under the Cannabis Act, so licensing, GPP and provincial retail rules still govern how you produce and sell.
• Health claims remain restricted. Do not market unauthorized CBD products for minor ailments, because that invites enforcement.
• Export and medical channels still work. Federally licensed processors can serve the medical stream and, with EU-GMP, international markets.
• Readiness pays off. Companies that already run strong quality systems will move fastest if a non-prescription pathway ever opens.

How to Stay Ready While the Rules Hold

• Keep CBD activities inside your federal cannabis licence and provincial authorizations.
• Review product claims so nothing implies an unauthorized health benefit.
• Maintain GPP-compliant production, testing and recordkeeping.
• Track Health Canada's Forward Regulatory Plan for any revival of the CBD pathway.
• If you serve or plan to serve the animal market, watch the separate veterinary pathway signals.
• Build NHP-style quality documentation now, so an NHP pathway would be an upgrade, not a rebuild.

Common Mistakes to Avoid

• Assuming the pathway is imminent. It has been paused and removed from the regulatory plan.
• Selling CBD as a natural health product. No CBD product is authorized as an NHP today.
• Making minor-ailment health claims. Claims outside authorized pathways are a compliance risk.
• Ignoring provincial rules. Even a compliant CBD product must move through the provincial cannabis retail system.
• Treating veterinary CBD as open. Non-prescription CBD veterinary drugs are not yet authorized either.

Frequently Asked Questions

Did Health Canada approve CBD as a natural health product in 2025?

No. Health Canada consulted on a possible pathway but did not adopt it. As of 2026, no CBD product is authorized as a natural health product, and CBD remains regulated under the Cannabis Act.

What did the 2025 CBD proposal actually propose?

It explored allowing certain CBD products to be sold without a prescription: for humans as amended natural health products, and for animals as non-prescription veterinary drugs, to treat minor ailments backed by evidence.

Why did the CBD pathway stall?

After the consultation, Health Canada said developing the pathway would need significant scientific, policy and regulatory resources that are not available at this time, and it removed the objective from its Forward Regulatory Plan.

Can I legally sell CBD without a cannabis licence in Canada?

No. CBD is controlled under the Cannabis Act. It can only be produced by federally licensed processors and sold through provincially authorized cannabis retailers or the medical stream.

How much CBD did the science advisory committee consider safe?

For healthy adults, the committee found low doses up to 200 mg a day taken orally for up to 30 days were safe and tolerable, but this did not apply to vulnerable groups. For animals it supported very low oral doses under veterinary oversight.

Could the CBD pathway come back?

Yes. Health Canada says it still values the work, so it could return to the agenda if resources and priorities shift. Businesses should watch the Forward Regulatory Plan and keep their quality systems ready.

Can I make health claims on CBD products now?

Only through authorized pathways. Marketing unapproved CBD products for minor ailments outside the cannabis or drug frameworks is a compliance risk and can trigger enforcement.

How MFLRC Can Help

At MF License and Regulatory Consultants (MFLRC), we help CBD, cannabis and natural health product companies read regulatory change accurately and act on it. When a proposal like the 2025 CBD pathway stalls, the risk is building a business around rules that never arrive. We help you stay compliant under the framework that is actually in force while keeping your quality systems ready for change. Our support includes regulatory gap assessments, licensing and market-entry strategy through our regulatory affairs and licensing services, quality system and site-licence readiness through our quality assurance support, and health-claim and label reviews. Whether you operate in the cannabis and hemp space or are watching the natural health products pathway, we help you move with confidence.

Want a clear read on how the CBD rules affect your product plans? Talk to MFLRC for practical, evidence-based guidance.

Conclusion

The 2025 CBD proposal was a genuine attempt to modernize how Canada regulates cannabidiol, and the science behind it, from the SAC-HPCC's dose guidance to the legislative review's recommendations, is real. But good intentions are not regulations. Health Canada has paused the pathway and taken it off its near-term plan, so the market remains where it was: CBD under the Cannabis Act, no non-prescription NHP route, and health claims tightly controlled. The smart move is to plan for the rules in force, stay compliant, and be ready to move quickly if the pathway ever returns.

Sources and References

• Health Canada, Towards a pathway for health products containing cannabidiol: Overview
• Health Canada, Health products containing cannabidiol: What we heard report
• Health Canada, Review of cannabidiol: Science Advisory Committee report
• Health Canada, Forward Regulatory Plan
• Government of Canada, Cannabis Act (S.C. 2018, c. 16)